Intracrine androgen biosynthesis and drug resistance

Abstract

Castration-resistant prostate cancer is the lethal form of prostate cancer and most commonly remains dependent on androgen receptor (AR) signaling. Current therapies use AR signaling inhibitors (ARSI) exemplified by abiraterone acetate, a P450c17 inhibitor, and enzalutamide, a potent AR antagonist. However, drug resistance to these agents occurs within 12-18 months and they only prolong overall survival by 3-4 months. Multiple mechanisms can contribute to ARSI drug resistance. These mechanisms can include but are not limited to germline mutations in the AR, post-transcriptional alterations in AR structure, and adaptive expression of genes involved in the intracrine biosynthesis and metabolism of androgens within the tumor. This review focuses on intracrine androgen biosynthesis, how this can contribute to ARSI drug resistance, and therapeutic strategies that can be used to surmount these resistance mechanisms.

Keywords

Prostate cancer / abiraterone acetate / enzalutamide / aldo-keto reductase 1C3 / androgen biosynthesis

References

[1] Siegel RL,Jermal A.Cancer statistics..CA Cancer J Clin2019;69:7-34

[2] Huggins CB.Studies on prostatic cancer 1. Effect of castration, estrogen and androgen injection on serum phosphatases in metatstatic carcinoma of the prostate..Cancer Res1941;1:293-397

[3] Huggins CB.Two principles in endocrine therapy of cancers: Hormone deprival and hormone interference..Cancer Res1965;25:1163-7

[4] Santen RJ,Max DT.Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma..J Clin Endocrinol Metab1984;58:397-400

[5] Seely JH.Phase III studies on prostatic cancer with leuprolide acetate..J Androl1987;8:S23-6

[6] Sharifi R.Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group..J Urol1990;143:68-71

[7] Schellhammer PF,Block NL.A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group..Cancer1996;78:2164-9

[8] Shah H.Therapy of advanced prostate cancer: targeting the androgen receptor axis in earlier lines of treatment..Target Oncol2018;13:679-89 PMCID:PMC6876618

[9] Yuan X,Chen S.Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis..Oncogene2014;33:2815-25 PMCID:PMC4890635

[10] Cannata DH,Levine AC.Androgen deprivation therapy as primary treatment for prostate cancer..J Clin Endcorinol Metab2012;97:360-5

[11] Attard G,Yap TA.Phase 1 clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven..J Clin Oncol2008;28:4563-71

[12] Knudsen K.Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer..Clin Cancer Res2009;15:4792-8 PMCID:PMC2842118

[13] Knudsen K.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer..Trends Endocrinol Metab2010;21:315-24 PMCID:PMC2862880

[14] Visakorpi T,Koivisto P.In vivo amplification of the androgen receptor gene and progression of human prostate cancer..Nat Genet1995;9:401-6

[15] Buchanan G,Scher HI.Collocation of androgen receptor gene mutations in prostate cancer..Clin Cancer Res2001;7:1273-81

[16] Taplin ME,Shuster TD.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer..N Engl J Med1995;332:1393-8

[17] Taplin ME,Ko YJ.Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist..Cancer Res1999;59:2511-5

[18] Dehm SM.Alternatively spliced androgen receptor variants..Endocr Relat Cancer2011;18:R183-96 PMCID:PMC3235645

[19] Chen S,Yuan X,Balk SP.Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1..Proc Natl Acad Sci U S A2006;103:15969-74 PMCID:PMC1635111

[20] Kemppainen JA,Sar M.Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones..J Biol Chem1992;267:968-74

[21] Labrie F,Simard J.DHEA and peripheral androgen and estrogen formation: intracrinology..Ann N Y Acad Sci1995;774:16-28

[22] Labrie F,Luu-The V.DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging..Steroids1998;63:322-8

[23] Cai C,Ng P.Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors..Cancer Res2011;71:6503-13 PMCID:PMC3209585

[24] Wright JL,Ostrander EA.Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes..Cancer Epidemiol Biomarkers Prev2011;20:619-27 PMCID:PMC3073610

[25] Clegg NJ,Joseph JD.ARN-509: a novel antiandrogen for prostate cancer treatment..Cancer Res2012;72:1494-503 PMCID:PMC3306502

[26] Fizazi K,Tammela TL.Darolutamide in nonmetastatic, castration-resistant prostate cancer..N Engl J Med2019;380:1235-46

[27] Fizazi K,Tombal B.Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer..Clin Genitourin Cancer2018;16:332-40

[28] Tran C,Clegg NJ.Development of a second-generation antiandrogen for treatment of advanced prostate cancer..Science2009;324:787-90 PMCID:PMC2981508

[29] de Bono JS,Molina A.Abiraterone and increased survival in metastatic prostate cancer..N Engl J Med2011;364:1995-2005 PMCID:PMC3471149

[30] Fizazi K,Molina A.Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study..Lancet Oncol2012;13:983-92

[31] Kwegyir-Afful AK,Ramamurthy VP.Galeterone and the next generation galeterone analogs, VNPP414 and VNPP433-3beta exert potent therapeutic effects in castration-/drug-resistant prostate cancer preclinical models in vitro and in vivo..Cancers (Basel)2019;11:1637 PMCID:PMC6895912

[32] Njar VC.Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer..J Med Chem2015;58:2077-87

[33] Rege J,Kasa-Vubu JZ.11-Ketotestosterone is the dominant circulating bioactive androgen during normal and premature adrenarche..J Clin Endocrinol Metab2018;103:4589-98 PMCID:PMC6226603

[34] Penning TM.Dehydroepiandrosterone (DHEA)-SO4 depot and castration-resistant prostate cancer..Vitam Horm2018;108:309-31 PMCID:PMC6226251

[35] Locke JA,Adomat HH.Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts..J Steroid Biochem Mol Biol2009;115:126-36

[36] Locke JA,Lubik AA.Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer..Cancer Res2008;68:6407-15

[37] Kumagai J,Erkens-Schulze S.Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis..Prostate2013;73:1636-50

[38] Fankhauser M,Macintyre G.Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer..Clin Cancer Res2014;20:5547-57

[39] Mitsiades N,Schultz N.Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors..Cancer Res2012;72:6142-52 PMCID:PMC3685485

[40] Chang KH,Papari-Zareei M.Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer..Proc Natl Acad Sci U S A2011;108:13728-33 PMCID:PMC3158152

[41] Sharifi N.Androstenedione is the preferred androgen source in hormone refractory prostate cancer--letter..Clin Cancer Res2014;20:4971

[42] Montgomery RB,Vessella R.Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth..Cancer Res2008;68:4447-54 PMCID:PMC2536685

[43] Auchus RJ.The backdoor pathway to dihydrotestosterone..Trends Endocrinol Metab2004;15:432-8

[44] Bauman DR,Williams MV.Identification of the major oxidative 3a-hydroxysteroid dehydrogenase in human prostate that converts 5a-andostane-3a,17b-diol to 5a-dihydrotestosterone. A potential therapeutic target for androgen dependent disease..Mol Endocrinol2006;20:444-58

[45] Mohler JL,Bai S.Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer..Cancer Res2011;71:1486-96 PMCID:PMC3075600

[46] Pretorius E,Vlok M.11-Ketotestosterone and 11-Ketodihydrotestosterone in castration resistant prostate cancer: potent androgens which can no longer be ignored..PLoS One2016;11:e0159867 PMCID:PMC4956299

[47] Pretorius E,Storbeck KH.A new dawn for androgens: novel lessons from 11-oxygenated C19 steroids..Mol Cell Endocrinol2017;441:76-85

[48] Schiffer L,Storbeck KH.Intracrine androgen biosynthesis, metabolism and action revisited..Mol Cell Endocrinol2018;465:4-26 PMCID:PMC6565845

[49] Barnard M,Mostaghel E.11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): implications for castration resistant prostate cancer..J Steroid Biochem Mol Biol2018;183:192-201 PMCID:PMC6283102

[50] Endo S,Kudo Y.Human dehydrogenase/reductase SDR family member 11 (DHRS11) and aldo-keto reductase 1C isoforms in comparison: substrate and reaction specificity in the reduction of 11-keto-C19-steroids..J Steroid Biochem Mol Biol2020;199:105586

[51] Penning TM,Rizner TL.Pre-receptor regulation of the androgen receptor..Mol Cell Endocrinol2008;281:1-8 PMCID:PMC2225387

[52] Steckelbroeck S,Gopishetty S,Penning TM.Human cytosolic 3a-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3b-hydroxysteroid dehydrogenase activity: Implications for steroid hormone metabolism and action..J Biol Chem2003;279:10784-95

[53] Penning TM,Jin Y.Identification of the molecular switch that regulates access of 5a-DHT to the androgen receptor..Mol Cell Endocrinol2007;265-266:77-82 PMCID:PMC1857325

[54] Gao X,Huang S.Functional silencing of HSD17B2 in prostate cancer promotes disease progression..Clin Cancer Res2019;25:1291-301 PMCID:PMC6377858

[55] Ko H,Chung YM.Loss of an androgen-inactivating and isoform-specific HSD17B4 splice form enables emergence of castration-resistant prostate cancer..Cell Rep2018;22:809-19 PMCID:PMC5798464

[56] Chouinard S,Bélanger A.UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells..J Biol Chem2007;282:33466-74

[57] Pâquet S,Grosse L.Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression..J Clin Endcrinol Metab2012;97:E428-32

[58] Tamae D,Montgomery B,Balk SP.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer..Chem Biol Interact2015;234:332-8 PMCID:PMC4414681

[59] Taplin ME,Logothetis CJ.Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study..J Clin Oncol2014;32:3705-15 PMCID:PMC4226804

[60] Arakawa H,Yanagihara C.Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions..Biochem Pharmacol2012;84:1070-7

[61] Green SM,Bullock K.Role of OATP transporters in steroid uptake by prostate cancer cells in vivo..Prostate Cancer Prostatic Dis2017;84:20-7 PMCID:PMC5762123

[62] Yang M,Mostaghel E.SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer..J Clin Oncol2012;29:2565-73 PMCID:PMC3138634

[63] Shapiro LJ.Steroid sulfatase deficiency and X-linked ichthyosis..Clin Biochem1979;12:205

[64] Hettel D,Alyamani M,Sharifi N.AR signaling in prostate cancer regulates a feed-forward mechanism of androgen synthesis by way of HSD3B1 upregulation..Endocrinology2018;159:2884-90 PMCID:PMC6456955

[65] Chang KH,Kuri B.A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer..Cell2013;154:1074-84 PMCID:PMC3931012

[66] Hearn JWD,Reichard CA.HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study..Lancet Oncol2016;17:1435-44 PMCID:PMC5135009

[67] Hearn JWD,Nakabayashi M.Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer..JAMA Oncol2018;4:558-62 PMCID:PMC5933377

[68] Li R,Sharma KK.Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer..Clin Cancer Res2012;18:3571-9

[69] Li Z,Alyamani M.Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer..Nature2015;523:347-51 PMCID:PMC4506215

[70] Stanbrough M,Ross K.Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer..Cancer Res2006;66:2815-25

[71] Hofland J,Dits NFJ.Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer..Cancer Res2010;70:1256-64

[72] Hamid AR,Verhaegh GW.Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer..Mol Med2012;18:1449-55 PMCID:PMC3563708

[73] Pfeiffer MJ,Sedelaar JP.Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer..Mol Med2011;17:657-64 PMCID:PMC3146625

[74] Knuuttila M,Kallio J.Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model..Am J Pathol2014;184:2163-73

[75] Powell K,Conley-LaComb MK.ERG/AKR1C3/AR constitutes a feed-forward loop for AR signaling in prostate Cancer Cells..Clin Cancer Res2015;21:2569-79 PMCID:PMC4976600

[76] Tian Y,Zhang H.AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression..Diagnostic Pathol2014;9:42-8 PMCID:PMC3939640

[77] Zhao J,Liu J.AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy..Prostate2019;79:1553-62

[78] Miyazaki Y,Shibuya S.Consecutive prostate cancer specimens revealed increased Aldo-Keto reductase family 1 member C3 expression with progression to castration-resistant prostate cancer..J Clin Med2019;8:E601 PMCID:PMC6571723

[79] Liu C,Zhu Y.Intracrine androgens and AKR1C3 activation confer resistance to Enzalutamide in prostate cancer..Cancer Res2015;75:1413-22 PMCID:PMC4383695

[80] Liu C,Lou W.Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer..Mol Cancer Ther2017;16:35-44 PMCID:PMC5222693

[81] Morsy A.Reversal of apalutamide and darolutamide aldo-keto reductase 1C3-mediated resistance by a small molecule inhibitor..ACS Chem Biol2020;15:646-50 PMCID:PMC7185239

[82] Platt A,Liu Y,Lazarus P.Impact of nonsynomynous single nucleotide polymorphsims on in vitro metabolism of exemestane by hepatic cytosolic reductases..Genomics2016;26:370-80 PMCID:PMC5088049

[83] Russell DW.Steroid 5apha-reductase: two genes/two enzymes..Annu Rev Biochem1994;63:25-61

[84] Ramos L,Chávez B.Mutational analysis of SRD5A2: from gene to functional kinetics in individuals with steroid 5α-reductase 2 deficiency..J Steroid Biochem Mol Biol2020;200:105691

[85] Makridakis N,Reichardt JK.Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue..Oncogene2004;23:7399-405

[86] Cantagrel V,Ng BG.SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder..Cell2010;142:203-17 PMCID:PMC2940322

[87] Burczynski ME,Penning TM.Isoform-specific induction of a Human Aldo-Keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH Activation catalyzed by human dihydrodiol dehydrogenase..Cancer Res1999;59:607-14

[88] Takahashi RH,Reid RE.The effectc of allelic variation in aldo-keto-reductase 1C2 on the in vitro metabolism of dihydrotestosterone..J Pharmaco Exp Ther2009;329:1032-9

[89] Zhu Z,Sergeeva O.Loss of dihydrotestosterone-inactivation activity promotes prostate cancer castration resistance detectable by functional imaging..J Biol Chem2018;293:17829-37 PMCID:PMC6240862

[90] Gauthier-Landry L,Barbier O.Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution..J Steroid Biochem Mol Biol2015;145:187-92

[91] Liu LL,Sun S.Mechanisms of the androgen receptor splicing in prostate cancer cells..Oncogene2014;33:3140-50 PMCID:PMC4553036

[92] Zhang A,Plymate S.Classical and non-classical roles for pre-receptor control of DHT metabolism in prostate cancer progression..Horm Cancer2016;7:104-13 PMCID:PMC4859429

[93] Vidal AC,Schildkraut JM.Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study..BMC Cancer2013;13:556 PMCID:PMC3924347

[94] Yepuru M,Kyulkarni A.Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth..Clin Cancer Res2013;19:5613-25

[95] Culig Z,Steiner H,Hobisch A.Expression and function of androgen receptor coactivators in prostate cancer..J Steroid Biochem Mol Biol2004;92:265-71

[96] He B,Minges JT.Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2..J Biol Chem2001;276:422293-301

[97] He B,Minges JT.Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction..J Biol Chem2002;277:25631-9

[98] Liu C,Armstrong CM.AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer..Mol Cancer Ther2019;18:1875-96 PMCID:PMC6995728

[99] Fan L,Hussain A.The steroidogenic enzyme AKR1C3 regulates stability of the ubiquitin ligase Siah2 in prostate cancer cells..J Biol Chem2015;290:20865-79 PMCID:PMC4543648

[100] Penning T.AKR1C3 (Type 5 17β-hydroxysteroid Dehydrogenase/Prostaglandin F Synthase): roles in malignancy and endocrine disorders..Mol Cell Endcorinol2019;489:82-91 PMCID:PMC6422768

[101] Thompson IM,Tangen CM.The influence of finasteride on the development of prostate cancer..Engl J Med2003;349:215-24

[102] Andriole GL,Brawley OW.Effect of dutasteride on the risk of prostate cancer..N Engl J Med2010;362:1192-202

[103] Penning TM,Auchus RJ.Structural and functional biology of aldo-keto reductase steroid-transofrming enzymes..Endocrine Rev2019;40:447-75 PMCID:PMC6405412

[104] Adeniji AO,Zang T.Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic acid as a potent and selective aldo-keto reductase 1C3 inhibitor..J Med Chem2016;59:7431-44 PMCID:PMC5149398

[105] Adeniji AO,Byrns MC.Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships..J Med Chem2012;55:2311-23 PMCID:PMC3298089

[106] Liedtke AJ,Chen M.Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17b-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer..J Med Chem2013;56:2429-46 PMCID:PMC3638264

[107] Lolli ML,Pippione AC.Bioisosteres of indomethacin as inhibitors of aldo-keto reductase 1C3..ACS Med Chem Lett2019;10:437-43 PMCID:PMC6466513

[108] Jamieson SM,Heinrich D.3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3..J Med Chem2012;55:7746-58

[109] Li C,Zheng X.In vitro CAPE inhibitory activity towards human AKR1C3 and the molecular basis..Chen Biol Inter2016;253:60-5

[110] Tian Y,Wang Y.Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells..Asian J Androl2016;18:607-12 PMCID:PMC4955188

[111] Heinrich DM,Jamieson SM.Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3..Eur J Med Chem2013;62:738-44

[112] Gazvoda M,Turk S.2,3-diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3)..Eur J Med Chem2013;62:89-97

[113] Kikuchi A,Azami H.In vitro and in vivo characterization of ASP9521: a novel selective, orally bioavailable inhibitor of 17b-hydroxysteroid dehydrogenase type 5 (17b-HSD5; AKR1C3)..Invest New Drugs2014;32:860-70

[114] Loriot Y,Jones RJ,Molife RL.Safety, tolerability and anti- tumor activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study..Invest New Drugs2014;32:995-1004

[115] Verma K,Zang T,Srivastava SK.AKR1C3 Inhibitor KV-37 exhibits antineoplastic effects and potentiates enzalutamide in combination therapy in prostate adenocarcinoma cells..Mol Cancer Ther2018;17:1833-45

[116] Hulcová D,Zemanová L.AKR1C3 inhibitory potency of naturally-occurring amaryllidaceae alkaloids of different structural types..Nat Prod Commun2017;12:245-6

[117] Byrns MC,Penning TM.Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights..J Steroid Biochem Mol Biol2011;125:95-104 PMCID:PMC3047600

[118] Penning TM.Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review..Expert Opin Ther Pat2017;27:1329-40 PMCID:PMC5724044

[119] Lin HK,Fung KM,Penning TM.Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3a-hydroxysteroid dehydrogenase/type 5 17b-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate..Steroids2004;69:795-801

[120] Rizner TL.Aldo-keto reductase 1C3-assessment as a new target for the treatment of endometriosis..Pharmacol Res2020;152:104446

[121] Chen M,Twenter BM.Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer..Bioorg Med Chem Lett2012;22:3492-7 PMCID:PMC3348334

[122] Wangtrakuldee P,Zang T.A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics..2019;192:105283 PMCID:PMC6625945

[123] Schweizer MT.Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer..Expert Opin Ther Targets2016;20:903-6 PMCID:PMC4975933

[124] Antonarakis ES,Wang H.AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer..N Engl J Med2014;371:1028-38 PMCID:PMC4201502

[125] Antonarakis ES,Luber B.Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer..JAMA Oncol2015;1:582-19 PMCID:PMC4537351

[126] Antonarakis ES,Luber B.Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide..J Clin Oncol2017;35:2149-56 PMCID:PMC5493048

[127] Rasool RU,Deng Q.A CDK7 inhibition suppresses castration-resistant prostate cancer through MED1 inactivation..Cancer Discov2019;9:1538-55 PMCID:PMC7202356

[128] Russo JW,Ye H,Chen S.Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer..Cancer Lett2018;438:97-104 PMCID:PMC6186500

[129] Narayanan S,Feldman D.Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy..Nat Rev Urol2016;13:47-60

[130] Oakley RH.The Biology of the glucocorticoid receptor: new signaling mechanisms in health and disease..J Allergy Clin Immunol2013;132:1033-44 PMCID:PMC4084612